Global Leading Market Research Publisher QYResearch announces the release of its latest report “Ex Vivo Organ Perfusion – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ex Vivo Organ Perfusion market, including market size, share, demand, industry development status, and forecasts for the next few years.
Ex vivo organ perfusion is a technique used in transplantation and research to preserve and evaluate organs outside of the body before transplantation. During ex vivo perfusion, the organ is connected to a perfusion system that delivers oxygenated blood or a specialized preservation solution to maintain the organ’s viability and function. This process allows for the assessment and optimization of organ function, as well as the potential for organ repair or treatment prior to transplantation. Ex vivo organ perfusion offers several advantages over traditional static cold storage, including the ability to assess organ viability, reduce ischemic injury, and potentially expand the donor pool by allowing for the use of marginal or extended criteria organs. Additionally, ex vivo perfusion enables researchers to study organ physiology, test new therapies, and improve transplantation outcomes.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5750670/ex-vivo-organ-perfusion
1. Industry Pain Points and the Shift Toward Normothermic Perfusion
Organ transplantation faces critical challenges: severe organ shortage (waitlist mortality 15-20%), ischemic injury during cold storage (static cold storage, SCS), and inability to assess organ viability before transplant. Marginal organs (extended criteria donors, donation after cardiac death – DCD) have higher discard rates (30-50%). Ex vivo organ perfusion addresses this with normothermic machine perfusion (37°C, oxygenated blood) that maintains organ metabolism, enables organ viability assessment (function, biomarkers), and allows organ preservation for extended periods (12-24+ hours). For transplant hospitals, organ banks, and research organizations, this technology reduces ischemic injury, expands donor pool, and improves transplant outcomes.
2. Market Size and Hyper-Growth Trajectory (2024–2032)
According to QYResearch, the global ex vivo organ perfusion market is projected to grow at a strong double-digit CAGR from 2026 to 2032. While specific market size figures are not disclosed in the provided abstract, industry data indicates accelerating adoption following clinical trial results (TransMedics OCS, OrganOx metra, XVIVO) and regulatory approvals. Market growth is driven by three factors: organ shortage crisis (100,000+ waitlist, 20+ deaths daily in US), expansion of DCD and extended criteria donor organs, and reimbursement for perfusion in transplant procedures.
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four explosive developments:
- FDA approvals: TransMedics OCS (heart, lung, liver) and OrganOx metra (liver) received expanded FDA approvals for DCD and extended criteria organs, driving 30% increase in perfusion system adoption.
- Clinical outcome data: Normothermic perfusion reduced post-transplant complications (primary graft dysfunction, biliary complications) by 40-50% vs. static cold storage (randomized trials).
- Portable perfusion devices: New portable systems (TransMedics OCS, XVIVO) enable organ transport during perfusion, extending preservation time and enabling cross-country matching.
- Research applications: Pharmaceutical companies adopted ex vivo perfusion for drug testing (hepatotoxicity, nephrotoxicity) and gene therapy delivery to donor organs.
4. Competitive Landscape and Key Suppliers
The market includes medical device companies and academic medical centers:
- TransMedics (US – OCS Heart, Lung, Liver), Lung Bioengineering (US – ex vivo lung perfusion), OrganOx (UK/US – metra liver perfusion), XVIVO (Sweden/US – perfusion systems), TNO (Netherlands – research), UHN (Canada – Toronto Ex Vivo Lung Perfusion), SCREEN (France), Bridge to Life (US – preservation solutions), Organ Recovery Systems (US), Institut Georges Lopez (France), Ebers (Germany), Penn Medicine (US – research), Johns Hopkins Medicine (US – research).
Competition centers on three axes: perfusion duration (hours), organ type (heart, liver, kidney, lung), and portability (stationary vs. transportable).
5. Segment-by-Segment Analysis: Type and Application
By Organ Type
- Liver Perfusion: Largest segment (~40% of market). Highest volume of marginal/DCD livers. OrganOx metra, TransMedics OCS Liver, XVIVO.
- Lung Perfusion: (~25% of market). Ex vivo lung perfusion (EVLP) for DCD lungs. TransMedics OCS Lung, Lung Bioengineering, XVIVO.
- Heart Perfusion: (~20% of market). TransMedics OCS Heart (only FDA-approved).
- Kidney Perfusion: (~15% of market). Bridge to Life, Organ Recovery Systems (hypothermic perfusion).
By End User
- Organ Transplant Specialist Hospitals: Largest segment (~70% of market). Transplant centers using perfusion for organ assessment and preservation.
- Organ Banks: (~20% of market). Organ procurement organizations (OPOs) using perfusion for organ transport and allocation.
- Pharmaceutical Research Organizations: (~10% of market). Drug safety testing (hepatotoxicity, nephrotoxicity), gene therapy delivery.
User case – DCD liver transplantation (OrganOx metra) : A transplant center used normothermic machine perfusion (OrganOx metra) for a DCD liver (donation after cardiac death, 30 minutes warm ischemia). Perfusion duration: 8 hours. Liver function assessed (bile production, lactate clearance, pH stability). Liver transplanted successfully. Recipient 1-year survival: 95% (similar to standard criteria donors). DCD liver discard rate reduced from 60% to 20%.
6. Exclusive Insight: Normothermic vs. Hypothermic Perfusion
| Parameter | Normothermic (37°C) | Hypothermic (4-10°C) | Advantage |
|---|---|---|---|
| Metabolism | Active (oxygenated blood) | Suppressed (preservation solution) | Normothermic: viability assessment |
| Ischemic injury | Reduced (continuous perfusion) | Static cold storage (ischemia continues) | Normothermic |
| Perfusion duration | 6-24 hours | 24-48 hours | Hypothermic (longer) |
| Organ assessment | Yes (function, biomarkers) | Limited (only vascular resistance) | Normothermic |
| Organ repair potential | Yes (therapeutics during perfusion) | No | Normothermic |
| Device complexity | Higher (pump, oxygenator, heater) | Lower (simple pump, chiller) | Hypothermic |
| Cost per perfusion | US$ 10,000-30,000 | US$ 3,000-8,000 | Hypothermic |
| Best for | DCD, marginal organs, viability assessment | Standard criteria donors, organ transport | — |
Technical challenge: Maintaining normothermic perfusion for extended periods (12-24 hours) requires glucose monitoring, electrolyte management, and waste product removal. Automated perfusion systems (TransMedics, OrganOx) include integrated sensors and feedback control.
User case – Extended perfusion for organ transport: A donor liver (Chicago) was allocated to a recipient in Boston (1,000 miles). Normothermic perfusion (TransMedics OCS) maintained liver function during 8-hour transport (ground + air). Organ transported warm, perfused, and viable. Recipient received liver immediately upon arrival (no cold storage). Post-transplant outcomes excellent.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (50% share). US (TransMedics, Lung Bioengineering, Bridge to Life, Organ Recovery Systems, Penn, Johns Hopkins). Strong FDA approvals, OPO adoption, transplant volume.
- Europe: Second-largest (30% share). UK (OrganOx), Sweden (XVIVO), Netherlands (TNO), France (SCREEN, Institut Georges Lopez), Germany (Ebers). Strong clinical research, early adoption.
- Asia-Pacific: Fastest-growing region (CAGR 20%+). China, Japan, South Korea, Australia. Increasing transplant volume, government investment.
- Rest of World: Latin America, Middle East. Emerging.
8. Conclusion
The ex vivo organ perfusion market is positioned for explosive growth through 2032, driven by organ shortage, DCD organ utilization, and clinical outcome improvements. Stakeholders—from transplant centers to organ procurement organizations—should prioritize normothermic perfusion for marginal/DCD organ assessment and repair, portable systems for organ transport, and automated devices for ease of use. By enabling normothermic machine perfusion and organ viability assessment, ex vivo organ perfusion expands donor pool and improves transplant success.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
